newsfilter
← Latest News
ClinicalTrials.gov·

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer - NCT04595565

Invasive disease free survival (iDFS) between patients treated with sacituzumab govitecan vs. treatment of physician's choice., To compare overall survival (OS) between patients treated with sacituzumab govitecan vs. treatment of physician's choice., Distant disease-free survival (DDFS) between patients treated with sacituzumab govitecan vs. treatment of physician's choice., (and 8 more...)